New hope for myelofibrosis patients with anemia: drug combo trial opens
NCT ID NCT07447817
First seen Mar 21, 2026 · Last updated Jun 03, 2026 · Updated 12 times
Summary
This phase II trial tests a combination of two drugs, selinexor and pacritinib, in people with myelofibrosis who have low red blood cells (anemia) and low platelets (thrombocytopenia) and have not yet received JAK inhibitor treatment. The main goal is to see if the combination can shrink the enlarged spleen, a common problem in myelofibrosis. The study will enroll 26 adults with intermediate- or high-risk disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
Contact
-
The University of Kansas Cancer Center-Westwood
Westwood, Kansas, 66205, United States
Contact
-
Wake Forest Baptist Health Comprehensive Cancer Center
Winston-Salem, North Carolina, 27157, United States
Contact
Conditions
Explore the condition pages connected to this study.